Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.57 USD | -1.06% | +0.39% | -4.81% |
Financials (USD)
Sales 2024 * | 31.42M | Sales 2025 * | 121M | Capitalization | 1.77B |
---|---|---|---|---|---|
Net income 2024 * | -312M | Net income 2025 * | -251M | EV / Sales 2024 * | 47 x |
Net cash position 2024 * | 291M | Net cash position 2025 * | 223M | EV / Sales 2025 * | 12.7 x |
P/E ratio 2024 * |
-5.51
x | P/E ratio 2025 * |
-7.44
x | Employees | 184 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.15% |
Latest transcript on Syndax Pharmaceuticals, Inc.
1 day | -1.06% | ||
1 week | +0.39% | ||
Current month | -13.57% | ||
1 month | -8.33% | ||
3 months | +3.63% | ||
6 months | +73.15% | ||
Current year | -4.81% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Metzger
CEO | Chief Executive Officer | 53 | 15-05-04 |
Peter Ordentlich
FOU | Founder | 55 | 05-10-10 |
Neil Gallagher
PSD | President | 60 | 23-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
BRD | Director/Board Member | 52 | 17-03-28 |
Dennis Podlesak
CHM | Chairman | 66 | 08-11-30 |
Pierre Legault
BRD | Director/Board Member | 63 | 17-01-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.12% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - | |
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 20.57 | -1.06% | 585,305 |
24-04-24 | 20.79 | -0.86% | 367,583 |
24-04-23 | 20.97 | +0.05% | 872,149 |
24-04-22 | 20.96 | +0.77% | 665,136 |
24-04-19 | 20.8 | +1.51% | 942,562 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.81% | 1.77B | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- SNDX Stock